NCT05787418

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (estimated)
• Sponsor: Huahui Health · Industry
• Sex: All
• Age: 12 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.

Detailed description

During this study, participants will receive HH-120 nasal spray treatment for 7 consecutive days, the efficacy and safety of HH-120 nasal spray will be assessed throughout the study period mainly based on the incidence of symptomatic SARS-CoV-2 infection and adverse events, respectively.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	HH-120 Nasal Spray	HH-120 nasal spray 8 times per day for 7 consecutive days
DRUG	Placebo	Placebo 8 times per day for 7 consecutive days

Timeline

• Start date: 2023-03-31
• Primary completion: 2025-12-31
• Completion: 2026-04-01
• First posted: 2023-03-28
• Last updated: 2024-10-10

Locations

2 sites across 1 country: China